Priority 15 from the Psoriasis PSP
|UNCERTAINTY: Could gene therapy help to treat psoriasis? (JLA PSP Priority 15)|
|JLA question ID||0072/15|
|Explanatory note||Not available for this PSP|
Han Evidence that apolipoprotein E (ApoE) polymorphisms are associated with the risk of psoriasis, especially ε2 and ε3 alleles. Further studies are needed.
Jia 2013 This meta-analysis evidenced that the TNF-a –238 and –308 promoter polymorphisms may play different roles in conferring susceptibility to psoriasis. Further functional and well-designed studies should be conducted to confirm these results.
Lee 2013 This meta-analysis evidenced that the IL-23R (rs11209026 and rs7530511) polymorphisms are associated with psoriasis risk in Europeans and that the IL-12B (rs6887695 and rs3212227) polymorphisms are associated with susceptibility to psoriasis in Europeans. Further studies needed.
Lee 2015 This meta-analysis provided evidence for the vascular endothelial growth factor VEGF +405 C/G polymorphism conferring susceptibility to psoriasis in Asians, with the -460 C/T and -1154 A/G polymorphisms conferring susceptibility to psoriasis in Europeans. Further investigation of the associations between VEGF polymorphisms and psoriasis susceptibility needed.
See data sheet for list of evidence considered.
|Health Research Classification System category||Skin|
|Extra information provided by this PSP|
|Original uncertainty examples||What gene therapy is being developed to help Psoriasis sufferers?|
|Submitted by||5 uncertainties were submitted around this question|
|PSP unique ID||0072|
|Total number of uncertainties identified by this PSP.||55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)|
|Date of priority setting workshop||17 September 2018|